Cediranib Maleate

• Cediranib Maleate is an investigational drug classified as a tyrosine kinase inhibitor.
• It has been studied for its use in several cancers, including ovarian cancer and non-small cell lung cancer.
• The drug primarily functions by inhibiting vascular endothelial growth factor (VEGF) receptors.
• Its mechanism of action disrupts the formation of new blood vessels that tumors need to grow.
• Common side effects include hypertension, fatigue, and gastrointestinal issues.

What is Cediranib Maleate?

Cediranib Maleate is an orally administered, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3, as well as platelet-derived growth factor receptor (PDGFR) beta and c-Kit. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). This compound is designed to interfere with the signaling pathways that promote the growth of new blood vessels, a process critical for tumor survival and proliferation, known as angiogenesis.

As an investigational agent, Cediranib Maleate has undergone extensive clinical trials to evaluate its safety and efficacy in various oncological settings. Its development highlights the ongoing efforts in targeted cancer therapies to disrupt specific molecular pathways that drive disease progression.

What is Cediranib Maleate Used For?

The primary focus of clinical investigations into cediranib maleate drug information has centered on its potential application in treating several types of cancer. It has been extensively studied, particularly in recurrent ovarian cancer, where it has shown promise in improving progression-free survival, often in combination with chemotherapy or as a maintenance therapy. Beyond ovarian cancer, Cediranib Maleate has also been explored in other malignancies, including non-small cell lung cancer (NSCLC), colorectal cancer, and soft tissue sarcoma, among others.

Its use is aimed at inhibiting the formation of new blood vessels (angiogenesis) that supply tumors with nutrients and oxygen, thereby starving the tumor and hindering its growth and metastasis. The specific indications for which it might be approved depend on the outcomes of ongoing and completed clinical trials and regulatory reviews by health authorities like the U.S. Food and Drug Administration (FDA).

Cediranib Maleate: Mechanism of Action and Side Effects

The cediranib maleate mechanism of action involves the potent inhibition of tyrosine kinases associated with VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3). These receptors play a crucial role in the signaling pathways that stimulate angiogenesis. By blocking these receptors, Cediranib Maleate prevents the binding of VEGF, a protein that promotes the formation of new blood vessels. This inhibition leads to a reduction in tumor vascularization, which in turn limits the supply of oxygen and nutrients to the tumor cells, ultimately impeding tumor growth and survival. Additionally, it inhibits PDGFR-beta and c-Kit, which can also contribute to tumor growth and angiogenesis.

Like all potent therapeutic agents, Cediranib Maleate is associated with a range of cediranib maleate side effects. These adverse reactions are generally manageable but can sometimes be serious. Common side effects observed in clinical trials include:

• Hypertension (high blood pressure)
• Fatigue and asthenia (weakness)
• Diarrhea
• Nausea and vomiting
• Proteinuria (protein in the urine)
• Dysphonia (hoarseness)
• Hypothyroidism (underactive thyroid)
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)

More serious, though less common, side effects can include arterial thromboembolic events, gastrointestinal perforations, and hemorrhage. Patients undergoing treatment with Cediranib Maleate require close monitoring for blood pressure, thyroid function, and other potential adverse events to ensure patient safety and optimize treatment outcomes. The management of these side effects often involves dose adjustments or supportive care, as determined by the treating physician.